Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

NCT00274742 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma, Relapsed

Interventions

BIOLOGICAL: Blinatumomab (MT103)

Sponsor

Amgen Research (Munich) GmbH